|ANX approval means 3 billions Market meeting is on Sept 1st ...!!!!!!!!!!!||DINPA...@GMAIL.COM||8/26/10 7:44 AM|
ADVENTRX Sets Meeting With FDA to Discuss ANX-530 NDA
Historical Stock Chart
6 Months : February 2010 to August 2010
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that
it will meet the U.S. Food and Drug Administration (FDA) in
D.C. during the last week of April 2010 to review the Company's New
Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion)
and the FDA's refusal-to-file letter.
ADVENTRX had requested a face-to-face meeting with the FDA to
understand its requirements and define the path to a successful
of an ANX-530 NDA at the earliest possible time.
"We look forward to meeting with the agency next month to clarify the
necessary steps for filing the ANX-530 NDA this year," said Brian M.
Culley, Chief Executive Officer of ADVENTRX.